References
- ShiYAuJSThongprasertSA prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)J Thorac Oncol20149215416224419411
- ZhangYSunYPanYFrequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosisClin Cancer Res20121871947195322317764
- MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
- ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
- MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
- HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
- YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
- JardimDLTangCGagliato DdeMAnalysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I ClinicClin Cancer Res201420246336634525326232
- LiSLiLZhuYCoexistence of EGFR with KRAS, or BRAF or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohortsBr J Cancer2014110112812282024743704
- KimGWSongJSChoiCMMultiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survivalLung Cancer201588213914625724261
- LeeJKShinJYKimSPrimary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory studyAnn Oncol20132482080208723559152
- WuCZhaoCYangYHigh discrepancy of driver mutations in patients with NSCLC and synchronous multiple lung ground-glass nodulesJ Thorac Oncol201510577878325629635
- LiHPanYLiYFrequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking doseLung Cancer201379181323098378
- SongZYuXZhangYClinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinomaLung Cancer2016101162127794403
- SongZYuXZhangYMutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinomaCancer Med20165102694270027554588
- SongZYuXZhangYClinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patientsCancer Biol Ther Epub2016916
- WonJKKeamBKohJConcomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitorAnn Oncol201526234835425403583
- ZhangXZhangSYangXFusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expressionMol Cancer2010918820624322
- ChaftJEArcilaMEPaikPKCoexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma – rationale for comprehensive mutation profilingMol Cancer Ther201211248549122135231
- YangJJZhangXCSuJLung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylationClin Cancer Res20142051383139224443522
- ZhouQZhangXCChenZHRelative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancerJ Clin Oncol201129243316332121788562
- CaiWLinDWuCIntratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinomaJ Clin Oncol201533323701370926416997